Biovail Tramadol Approval Awaits New Trade Name
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA "approvable" letter for the orally disintegrating tablet formulation of the analgesic cites labeling issues, including the product's name. Biovail's extended-release version of tramadol is approvable under the brand Ralivia ER.
You may also be interested in...
Biovail’s Tramadol ER Still Needs Clinical Trial, FDA Says
Biovail will undertake a new clinical trial for its extended release tramadol following FDA’s preliminary comments on the company’s response to an “approvable” letter. Biovail expects to submit data from the new clinical trial in late 2005 or early 2006.
Biovail’s Tramadol ER Still Needs Clinical Trial, FDA Says
Biovail will undertake a new clinical trial for its extended release tramadol following FDA’s preliminary comments on the company’s response to an “approvable” letter. Biovail expects to submit data from the new clinical trial in late 2005 or early 2006.
Medication Errors, Drug Packaging On USP's Agenda
The U.S. Pharmacopeia will hear comments and vote on 12 proposed resolutions at its convention in Washington, D.C. March 9-13. One proposal calls for "further consideration" of drug packaging for increasingly complex ingredients and dosage forms.